The company is pursing therapeutic applications of its ACE2 enzyme variants, which have been demonstrated in vitro to intercept SARS-CoV-2.

The patented proteins were developed in the lab of Daniel Batlle, PhD, at Northwestern Feinberg University School of Medicine. The goal of the proteins is to intercept the coronavirus before it gets to the natural receptor in cell membranes.

The study showed that in human kidney organoids, infection by SARS-CoV-2 can be neutralized by the novel ACE2 protein. The company states that the proof-of-concept study provides evidence that the modified ACE2 protein will be efficacious to prevent and treat COVID-19 infection in humans.

The company plans on conducting preinvestigational new drug safety studies, which are required for clinical trials in patients with COVID-19.

The product is also being developed for the treatment of acute kidney injury and chronic kidney disease.

Acute SARS-CoV-2 infection elicits distinct antibody, T-cell responses
An analysis of antibody and T-cell responses during the entire timeline of SARS-CoV-2 infection reveals the different ways the immune system responds...

SARS-CoV-2 mutation doesn't affect viral spread, but may limit therapies
As SARS-CoV-2 spreads around the globe, mutations of the virus are inevitable. An international team of researchers sought to define the effects of a...

2003 SARS-CoV antibodies may provide some protection from SARS-CoV-2
A new study shows that antibodies against the original 2003 SARS-CoV also react with the current SARS-CoV-2 strain, but only with limited effectiveness....